Adjunctive raloxifene for postmenopausal women with schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials.

Abstract

OBJECTIVE:

Raloxifene, a selective estrogen receptor modulator, has been used in treating postmenopausal women with schizophrenia with inconsistent results. This meta-analysis of randomized, double-blind, placebo-controlled trials (RCTs) examined its efficacy and safety for postmenopausal women with schizophrenia.

METHOD:

Standardized mean differences (SMDs) and risk ratio (RR) together with their 95% confidence intervals (CIs) were calculated using the random effects model.

RESULTS:

The meta-analysis included 5 RCTs (n = 240) comparing raloxifene (n = 125, 60 or 120 mg/day) with placebo (n = 115). Adjunctive raloxifene outperformed placebo with regard to the Positive and Negative Syndrome Scale (PANSS) total psychopathology [n = 240, SMD:-0.64 (95%CI:-0.90, -0.37), P < 0.00001; I2 = 0%], positive symptoms [n = 240, SMD:-0.49 (95%CI:-0.81, -0.16), P = 0.003; I2 = 29%], negative symptoms [n = 240, SMD:-0.43 (95%CI:-0.68, -0.17), P = 0.001; I2 = 0%], and general psychopathology scores [n = 240, SMD:-0.66 (95%CI:-0.92, -0.39), P < 0.00001; I2 = 0%]. Both groups had similar rates of adverse events and discontinuation (n = 159, RR: 1.32 (95%CI: 0.65, 2.70), P = 0.44, I2 = 0%).

CONCLUSION:

Adjunctive raloxifene appears to be effective and safe in improving psychotic symptoms for postmenopausal women with schizophrenia. Review registration: CRD 42017059946.

• Authors: Xiao-Min Zhu, Wei Zheng, Xiao-Hong Li, Dong-Bin Cai, Xin-Hu Yang, Gabor S Ungvari, Chee H Ng, Xiao-Ping Wang, Jayashri Kulkarni, Jasmin Grigg, Yu-Ping Ning, Yu-Tao Xiang
• Journal: Schizophrenia research (Schizophr Res) Vol. 197 Pg. 288-293 (07 2018) ISSN: 1573-2509 [Electronic] Netherlands
• PMID: 29395611 (Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2018. Published by Elsevier B.V.

Chemical References

• Antipsychotic Agents
• Selective Estrogen Receptor Modulators
• Raloxifene Hydrochloride

Topics

• Antipsychotic Agents (pharmacology)
• Drug Therapy, Combination
• Female
• Humans
• Middle Aged
• Outcome Assessment, Health Care (statistics & numerical data)
• Postmenopause
• Raloxifene Hydrochloride (pharmacology)
• Randomized Controlled Trials as Topic (statistics & numerical data)
• Schizophrenia (drug therapy)
• Selective Estrogen Receptor Modulators (pharmacology)